Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA4 | P48058 | 11/20 | 0.67 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.49 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.49 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | GBA1 | P04062 | 1/20 | 0.41 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL338392 | 1.00 | GRIA4 (0.67) | GRIA4TAAR1AOC3GRIA2LMNA | |
| SCHEMBL6759326 | 1.00 | GRIA4 (0.67) | GRIA4TAAR1AOC3GRIA2LMNA | |
| SCHEMBL6565123 | 0.91 | GRIA4 (0.68) | GRIA4GRIA2 | |
| SCHEMBL5992695 | 0.87 | GRIA4 (0.71) | GRIA4GRIA2 | |
| SCHEMBL6555617 | 0.84 | GRIA4 (0.60) | GRIA4GRIA2 | |
| SCHEMBL6554706 | 0.84 | GRIA4 (0.60) | GRIA4GRIA2 | |
| SCHEMBL6847064 | 0.84 | GRIA4 (0.60) | GRIA4GRIA2 | |
| SCHEMBL7031129 | 0.84 | GRIA4 (0.60) | GRIA4GRIA2 | |
| SCHEMBL6554686 | 0.84 | GRIA4 (0.60) | GRIA4GRIA2 | |
| SCHEMBL6936169 | 0.84 | GRIA4 (0.60) | GRIA4GRIA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1390072-A2 | USE OF AN AMPA RECEPTOR POTENTIATOR FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF TYPE 2 DIABETES | ELI LILLY AND COMPANY (US) | 2004-02-25 | — | — | EP | disclosed |
| WO-2002089848-A2 | USE OF AN AMPA RECEPTOR POTENTIATOR FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF TYPE 2 DIABETES | ELI LILLY AND COMPANY (US) | 2002-11-14 | — | — | WO | disclosed |
| WO-2001089510-A2 | USE OF AN AMPA RECEPTOR POTENTIATOR FOR THE TREATMENT OF OBESITY | ELI LILLY AND COMPANY (US) | 2001-11-29 | — | — | WO | disclosed |